Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil

MT Newswires Live

Aug 28

Incyte (INCY) partner Knight Therapeutics has submitted a supplemental application to the Brazilian health regulatory agency seeking approval for an additional indication for Minjuvi in combination with other medicines as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, the company said Thursday.

The drug combination consists of Minjuvvi and lenalidomide added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, the company said.

The application is meant to expand Minjuvi in earlier lines of cancer therapy in Brazil, the company said.

The supplemental submission is based on previous approvals and results from a phase 3 trial, the company said.

Knight has exclusive supply and distribution rights for Incyte's Minjuvi, which is also called Monjuvi, in the US and parts of Latin America, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/2662061139"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662061139\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662061139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 18:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662061139","market":"hk","top_or_hot":-1,"title":"Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil","media":"MT Newswires Live","content":"<html><body><p> Incyte (INCY) partner Knight <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has submitted a supplemental application to the Brazilian health regulatory agency seeking approval for an additional indication for Minjuvi in combination with other medicines as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, the company said Thursday.</p><p>The drug combination consists of Minjuvvi and lenalidomide added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, the company said.</p><p>The application is meant to expand Minjuvi in earlier lines of cancer therapy in Brazil, the company said.</p><p>The supplemental submission is based on previous approvals and results from a phase 3 trial, the company said.</p><p>Knight has exclusive supply and distribution rights for Incyte's Minjuvi, which is also called Monjuvi, in the US and parts of Latin America, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-28 18:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Incyte (INCY) partner Knight <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has submitted a supplemental application to the Brazilian health regulatory agency seeking approval for an additional indication for Minjuvi in combination with other medicines as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, the company said Thursday.</p><p>The drug combination consists of Minjuvvi and lenalidomide added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, the company said.</p><p>The application is meant to expand Minjuvi in earlier lines of cancer therapy in Brazil, the company said.</p><p>The supplemental submission is based on previous approvals and results from a phase 3 trial, the company said.</p><p>Knight has exclusive supply and distribution rights for Incyte's Minjuvi, which is also called Monjuvi, in the US and parts of Latin America, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2662061139","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662061139","pubTimestamp":1787912783,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Incyte  partner Knight Therapeutics has submitted a supplemental application to the Brazilian health regulatory agency seeking approval for an additional indication for Minjuvi in combination with other medicines as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, the company said Thursday.The drug combination consists of Minjuvvi and lenalidomide added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, the company said.The application is meant to expand Minjuvi in earlier lines of cancer therapy in Brazil, the company said.The supplemental submission is based on previous approvals and results from a phase 3 trial, the company said.Knight has exclusive supply and distribution rights for Incyte's Minjuvi, which is also called Monjuvi, in the US and parts of Latin America, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EWZS":"MSCI巴西小盘股ETF-iShares","BK4532":"文艺复兴科技持仓","BK4588":"碎股","BK4550":"红杉资本持仓","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","IDNA":"iShares Genomics Immunology and Healthcare ETF"},"translate_title":"Incyte 合作伙伴 Knight 寻求巴西 Minjuvi 组合的补充批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1.5,"EWZS":1.5,"IDNA":0.6},"content_text":"Incyte (INCY) partner Knight Therapeutics has submitted a supplemental application to the Brazilian health regulatory agency seeking approval for an additional indication for Minjuvi in combination with other medicines as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, the company said Thursday.The drug combination consists of Minjuvvi and lenalidomide added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, the company said.The application is meant to expand Minjuvi in earlier lines of cancer therapy in Brazil, the company said.The supplemental submission is based on previous approvals and results from a phase 3 trial, the company said.Knight has exclusive supply and distribution rights for Incyte's Minjuvi, which is also called Monjuvi, in the US and parts of Latin America, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}